SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 926-935. Prepublished online as a Blood First Edition Paper on September 26, 2006; DOI 10.1182/blood-2006-01-024729. This Article Full Text (PDF) All Versions of this Article: blood-2006-01-024729v1 109/3/926    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Schultz, K. R. Articles by Camitta, B. M. Search for Related Content PubMed PubMed Citation Articles by Schultz, K. R. Articles by Camitta, B. M. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted January 24, 2006 Accepted September 10, 2006 Risk and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) Kirk R. Schultz*, D. Jeanette Pullen, Harland N. Sather, Jonathan J. Shuster, Meenakshi Devidas, Michael J. Borowitz, Andrew J. Carroll, Nyla A. Heerema, Jeffrey E. Rubnitz, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Stephen P. Hunger, William L. Carroll, Paul S. Gaynon, and Bruce M. Camitta Children's Oncology Group Department of Pediatrics, University of British Columbia, Vancouver, BC Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS Department of Preventative Medicine, University of Southern California, Los Angeles, CA Department of Epidemiology & Health Policy Research, University of Florida, Gainesville, FL Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD Department of Genetics, University of Alabama at Birmingham, Birmingham, AL Department of Pathology, Division of Clinical Pathology, The Ohio State University, Columbus, OH Oncology, St. Jude Children's Research Hospital Memphis, Memphis, TN Department of Pediatrics, UCSF School of Medicine, San Francisco, CA Department of Pediatrics, NYU Medical Center, New York, NY UT Southwestern Medical Center, Dallas, TX Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL Department of Hematology-Oncology, Children's Hospital, Los Angeles, CA Department of Pediatrics, Medical College of Wisconsin and Children's Hospital of Wisconsin, WI * Corresponding author; email: kschultz{at}interchange.ubc.ca. The Children's Cancer Group (CCG) and the Pediatric Oncology Group (POG) joined to form the Children's Oncology Group (COG), in 2000. This merger allowed analysis of clinical, biological, and early response data predictive of event-free survival (EFS) in acute lymphoblastic leukemia (ALL) to develop a new classification system and treatment algorithm. From 11,779 children (1 to 21.99 years) with newly diagnosed B-precursor ALL consecutively enrolled by the CCG (December 1988 to August 1995, N = 4986) and POG (January 1986 to November 1999, N = 6793), we retrospectively analyzed 6238 patients (CCG 1182, POG 5056) with informative cytogenetic data. Four risk groups were defined as very high risk (VHR, 5-year EFS 45%), lower risk (5-year EFS 85%) and standard and high risk as those remaining in the respective NCI risk groups. VHR criteria included extreme hypodiploidy (<44 chromosomes), t(9;22) and/or BCR-ABL, and induction failure. Lower risk patients were NCI standard risk with either t(12;21) (TEL-AML1) or simultaneous trisomies of chromosomes 4, 10, and 17. Even with treatment differences, there was high concordance between the CCG and POG analyses. The COG risk classification scheme is being used for division of B-precursor ALL into lower (27%), standard (32%), high (37%), and VHR (4%) risk groups based on age, WBC, cytogenetics, day 14 marrow response and end induction MRD by flow cytometry in COG trials. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. R. Verneris, C. G. Brunstein, J. Barker, M. L. MacMillan, T. DeFor, D. H. McKenna, M. J. Burke, B. R. Blazar, J. S. Miller, P. B. McGlave, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units Blood, November 5, 2009; 114(19): 4293 - 4299. [Abstract] [Full Text] [PDF] G. Basso, M. Veltroni, M. G. Valsecchi, M. N. Dworzak, R. Ratei, D. Silvestri, A. Benetello, B. Buldini, O. Maglia, G. Masera, et al. Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow J. Clin. Oncol., November 1, 2009; 27(31): 5168 - 5174. [Abstract] [Full Text] [PDF] K. R. Schultz, W. P. Bowman, A. Aledo, W. B. Slayton, H. Sather, M. Devidas, C. Wang, S. M. Davies, P. S. Gaynon, M. Trigg, et al. Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study J. Clin. Oncol., November 1, 2009; 27(31): 5175 - 5181. [Abstract] [Full Text] [PDF] A. E. Seif, D. M. Barrett, M. Milone, V. I. Brown, S. A. Grupp, and G. S. D. Reid Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses Blood, September 17, 2009; 114(12): 2459 - 2466. [Abstract] [Full Text] [PDF] C. A. Scrideli, J. G. Assumpcao, M. A. Ganazza, M. Araujo, S. R. Toledo, M. L. M. Lee, E. Delbuono, A. S. Petrilli, R. P. Queiroz, A. Biondi, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups Haematologica, June 1, 2009; 94(6): 781 - 789. [Abstract] [Full Text] [PDF] D. French, W. Yang, C. Cheng, S. C. Raimondi, C. G. Mullighan, J. R. Downing, W. E. Evans, C.-H. Pui, and M. V. Relling Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia Blood, May 7, 2009; 113(19): 4512 - 4520. [Abstract] [Full Text] [PDF] J. J. Yang, C. Cheng, W. Yang, D. Pei, X. Cao, Y. Fan, S. B. Pounds, G. Neale, L. R. Trevino, D. French, et al. Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia JAMA, January 28, 2009; 301(4): 393 - 403. [Abstract] [Full Text] [PDF] D. Bhojwani, H. Kang, R. X. Menezes, W. Yang, H. Sather, N. P. Moskowitz, D.-J. Min, J. W. Potter, R. Harvey, S. P. Hunger, et al. Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study J. Clin. Oncol., September 20, 2008; 26(27): 4376 - 4384. [Abstract] [Full Text] [PDF] M. J. Borowitz, M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood, June 15, 2008; 111(12): 5477 - 5485. [Abstract] [Full Text] [PDF] J. E. Rubnitz, D. Wichlan, M. Devidas, J. Shuster, S. B. Linda, J. Kurtzberg, B. Bell, S. P. Hunger, A. Chauvenet, C.-H. Pui, et al. Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study J. Clin. Oncol., May 1, 2008; 26(13): 2186 - 2191. [Abstract] [Full Text] [PDF] F. E. Craig and K. A. Foon Flow cytometric immunophenotyping for hematologic neoplasms Blood, April 15, 2008; 111(8): 3941 - 3967. [Abstract] [Full Text] [PDF] S. M. Davies, M. J. Borowitz, G. L. Rosner, K. Ritz, M. Devidas, N. Winick, P. L. Martin, P. Bowman, J. Elliott, C. Willman, et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group Blood, March 15, 2008; 111(6): 2984 - 2990. [Abstract] [Full Text] [PDF] V. Pullarkat, M. L. Slovak, K. J. Kopecky, S. J. Forman, and F. R. Appelbaum Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study Blood, March 1, 2008; 111(5): 2563 - 2572. [Abstract] [Full Text] [PDF] B. Lange A FISH 'n chips appetizer Blood, January 15, 2008; 111(2): 480 - 481. [Full Text] [PDF] D. Campana Molecular Determinants of Treatment Response in Acute Lymphoblastic Leukemia Hematology, January 1, 2008; 2008(1): 366 - 373. [Abstract] [Full Text] [PDF] N. L. Seibel Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls Hematology, January 1, 2008; 2008(1): 374 - 380. [Abstract] [Full Text] [PDF] V. Bedell, S. J. Forman, K. Gaal, V. Pullarkat, L. M. Weiss, and M. L. Slovak Successful Application of a Direct Detection Slide-Based Sequential Phenotype/Genotype Assay Using Archived Bone Marrow Smears and Paraffin Embedded Tissue Sections J. Mol. Diagn., November 1, 2007; 9(5): 589 - 597. [Abstract] [Full Text] [PDF] M. H. Kang, Y. H. Kang, B. Szymanska, U. Wilczynska-Kalak, M. A. Sheard, T. M. Harned, R. B. Lock, and C. P. Reynolds Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo Blood, September 15, 2007; 110(6): 2057 - 2066. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020